Surgical Nivolumab And Ipilimumab For Recurrent GBM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Bristol-Myers Squibb
Related studies linked through entity extraction aliases.
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE1
Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant
- Status
- WITHDRAWN
- Phase
- PHASE2
The IRMI-FMT Trial
- Status
- TERMINATED
- Phase
- NA
Accelerated Radio-Immunotherapy for Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab+Ipilimumab+RT in MSS mCRC
- Status
- UNKNOWN
- Phase
- PHASE2
Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities
- Status
- TERMINATED
- Phase
- PHASE2
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
- Status
- RECRUITING
- Phase
- PHASE1
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
- Status
- COMPLETED
- Phase
- PHASE1
Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
- Status
- SUSPENDED
- Phase
- PHASE1/PHASE2
A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants
- Status
- COMPLETED
- Phase
- PHASE1
COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications
- Status
- COMPLETED
- Phase
- N/A